Wireless Cardiac Monitor Uses Cellular Phone Technology

Transmission occurs without patient interaction and without connection through a separate cell phone, reducing potential anomalies in the prescribed testing routine and avoiding the possibility of the patient forgetting to carry the cell phone. The ER920W enhances diagnostic yield with embedded algorithms that automatically detect, record and immediately transmit asymptomatic events such as atrial fibrillation, bradycardia, tachycardia, and cardiac pause.

The monitor's telecommunications architecture, including cellular network, Internet, and the proprietary management software interface, allows for bidirectional data flow, so the physician can monitor the patient's cardiac events and remotely program the device as required. The cellular transmitter embedded in the ER920W uses a quad-band modem for maximum flexibility and is compatible with both Global System for Mobile (GSM) and General Packet Radio Service (GPRS) cellular networks. The ER920W Wireless Cardiac Arrhythmia Monitor is manufactured by Braemar (Minneapolis, MN, USA), a subsidiary of Biotel (Eagan, MN, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"The ER920W is an advanced arrhythmia monitor with proprietary technology that we believe represents the next generation of cardiac event monitoring,” said Harry Strandquist, president of Braemar. "The ER920W provides faster patient diagnosis, improves patient compliance, and is far superior to the current cumbersome transmission method. This device is the first in a series of Braemar wireless arrhythmia monitoring products currently under development.”

Cardiac arrhythmia monitors are worn by patients for up to 30 days to document and record transient cardiac events. Recording of symptomatic events such as syncope, palpitations, dizziness, chest discomfort, and shortness of breath is activated by the patient.


Related Links:
Biotel